| Flavius Martin |
Flavius Martin is currently the Executive Vice President-Research at Gilead Sciences, Inc. Prior to this, he worked as the Vice President-Research Biology at Amgen, Inc. Dr. Martin holds a doctorate degree from Universitatea de Medicina si Farmacie Victor Babes. |
| Daniel P. O'Day |
Daniel P. O'Day is currently the Chairman & Chief Executive Officer at Gilead Sciences, Inc. He is also the Chairman at the Pharmaceutical Research & Manufacturers of America. In addition, he holds positions as Director at the Pharmaceutical Manufacturers Association of America and Director at Shanghai Roche Pharmaceuticals Ltd. Previously, O'Day served as the Chief Executive Officer of Roche Pharmaceuticals, Inc. from 2012 to 2018. He also held the position of President & Chief Executive Officer at Roche Molecular Systems, Inc. O'Day has experience as a Director at Genentech, Inc. and Chugai Pharmaceutical Co., Ltd. He was also a Director at Roche Diagnostics GmbH from 2010 to 2012. O'Day served as a Director at Foundation Medicine, Inc. and Flatiron Health, Inc. as well. O'Day's education includes an MBA from The Trustees of Columbia University in The City of New York, which he received in 1997. He also holds an undergraduate degree from Georgetown University, which he obtained in 1986. |
| Merdad V. Parsey |
Merdad V. Parsey is currently serving as an Independent Director at Sagimet Biosciences, Inc. since 2019, as well as a Director at Arcus Biosciences, Inc. since 2020. He is also a Director at Transcelerate Biopharma, Inc. Additionally, he holds the position of Chief Medical Officer at Gilead Sciences, Inc. since 2019. In his former roles, Dr. Parsey worked as an Associate Medical Director at Merck & Co., Inc. He also served as a Senior Medical Director at Regeneron Pharmaceuticals, Inc. from 2002 to 2004. He held the position of Senior Medical Director at Sumitomo Pharma America, Inc. Furthermore, he worked as the Director-Critical Care Medicine at New York University School of Medicine. He also served as the Senior Vice President-Early Clinical Development at Genentech, Inc. and was a Member of the Roche Group. Dr. Parsey obtained his doctorate degree from the University of Maryland. |
| Christi L. Shaw |
Christi L. Shaw founded More Moments More Memories Foundation. Ms. Shaw also currently works at Biotechnology Innovation Organization, as Executive Director from 2014, Avantor, Inc., as Independent Director from 2018, and Beam Therapeutics, Inc., as Director from 2023. Ms. Shaw also formerly worked at Kite Pharma, Inc., as Chief Executive Officer from 2019 to 2023, Janssen Pharmaceuticals, Inc., as Group Product Director in 2004, Healthcare Leadership Council, as Director, The Young Women's Leadership Network, Inc., as Director, Johnson & Johnson, as Principal, Eli Lilly & Co., as President-Bio Medicines & Senior Vice President from 2017 to 2019, Novartis Oncology, Inc., as Head-North American Region, Novartis Pharmaceuticals Corp., as President & Country Head-US from 2014 to 2016, Ethicon Corp., as VP-New Business Development & Strategic Analytics, and Concord Health Partners LLC, as Advisor. Ms. Shaw received her undergraduate degree from Iowa State University and Masters Business Admin degree from the University of Wisconsin. |
| Johanna Mercier |
Johanna Mercier is currently an Independent Director at Neurocrine Biosciences, Inc., a Director at Robert Wood Johnson University Hospital, Inc., a Director at Arcus Biosciences, Inc., a Director at Leonard D Schaeffer Center For Health Policy & Economics, a Chief Commercial Officer at Gilead Sciences, Inc., and a Member at World 50, Inc. She previously worked as the President-US Commercial at Bristol Myers Squibb Co. Ms. Mercier holds an MBA from Concordia University and an undergraduate degree from the University of Montréal. |
| Andrew D. Dickinson |
Andrew D. Dickinson is currently serving as the President, Treasurer & Director at Immunomedics, Inc. He is also a Director at Sutter Health and Forty Seven, Inc. Additionally, he holds positions as a Director at Fosun Kite Biotechnology Co., Ltd. and Gilead Sciences Ltd. In the future, he will be a Non-Independent Non-Executive Director at Galapagos NV and the President, Treasurer & Director at CymaBay Therapeutics, Inc. Previously, he worked as the Chief Financial Officer at Gilead Sciences, Inc. He has also held positions as the Secretary, Vice President & General Counsel at Gilead Colorado, Inc. and as the Co-Head-Healthcare Investment Banking at Lazard, Inc. Prior to that, he was a Founding Partner at Kendall Dickinson & Koenig LLC. Mr. Dickinson completed his graduate degree at Loyola University of Chicago in 1996 and his undergraduate degree at The University of Colorado in 1993. |
| Javier J. Rodriguez |
Javier J. Rodriguez is the founder of DomoBlue SL, which was founded in 2004. He served as the Chairman from 2009 to 2012. Mr. Rodriguez's current job(s) include being the Chief Executive Officer & Director at DaVita, Inc. since 2019, the Chief Executive Officer at CEO Action For Diversity & Inclusion, an Independent Director at Gilead Sciences, Inc. since 2020, and a Director at Denver Metro Chamber of Commerce. He also holds the position of Senior Vice President at Renal Care Centers Corp. since 1998. Mr. Rodriguez's former job(s) include being the President & Chief Executive Officer at DaVita Kidney Care Contracting LLC from 2014 to 2019, and the Director of Operations at CBS Marketing, Inc. in 2009. He also worked as a Principal at Baxter Healthcare Corp. from 1995 to 1996. Mr. Rodriguez's education history includes an undergraduate degree from Boston College and an MBA from Harvard Business School. |
| Anthony Welters |
Anthony Welters founded AmeriChoice Corp. in 1989, where he worked as President & Chief Executive Officer from 1989 to 2002, Somatus, Inc. in 2016, where he is working as Chairman from 2016, and CINQ Care, Inc. in 2021, where he is working as Chairman & Chief Executive Officer from 2021. Mr. Welters also currently works at New York University, as Vice Chairman, Morehouse School of Medicine, as Chairman, New York University School of Law, as Chairman, and various other companies. Mr. Welters also formerly worked at C. R. Bard, Inc. (New Jersey), as Independent Director from 2011 to 2017, Qwest Communications International, Inc., as Director from 2006 to 2011, West Pharmaceutical Services, Inc., as Independent Director from 1997 to 2016, and various other companies. Mr. Welters received his undergraduate degree from Manhattanville College and graduate degree from New York University School of Law. |
| Jeffrey A. Bluestone |
Jeffrey A. Bluestone is the founder of Celsius Therapeutics, Inc. (founded in 2018), Xconomy, Inc. (founded in 2007), Immune Tolerance Network (founded in 1999), and Sonoma Biotherapeutics, Inc. (founded in 2019). He is currently the Vice Chairman at The Parker Institute For Cancer Immunotherapy since 2015, an Independent Director at Gilead Sciences, Inc. since 2020, a Professor at The University of California, San Francisco, and a Member of both the American Academy of Arts & Sciences and the National Academy of Medicine (United States). He previously served as an Independent Director at Provention Bio, Inc. from 2019 to 2022, a Director at Rheos Medicines, Inc., and the Director & Professor at The Ben May Department For Cancer Research. Dr. Bluestone received a graduate degree from Rutgers State University of New Jersey and a doctorate degree from Weill Cornell Graduate School of Medical Sciences. |
| Kelly A. Kramer |
Kelly A. Kramer is an Independent Director at Gilead Sciences, Inc., a Director at Coinbase, Inc., a Director at Coinbase Global, Inc., and a Senior Advisor at Consello Capital LLC. She is also a Director at City Year San Jose and an Independent Director at Snowflake, Inc. In the past, she was the Chief Financial Officer & Executive Vice President at Cisco Systems, Inc., the Chief Financial Officer at Global Life Sciences Solutions USA LLC, and the CFO-Healthcare Systems Business & Vice President at GE Healthcare, Inc. She also served as a Director at Figma, Inc. Ms. Kramer received her undergraduate degree from Purdue University in 1989. |
| Jacqueline K. Barton |
Jacqueline K. Barton was the founder of GeneOhm Sciences, Inc. (founded in 2001) where she served as the Director from 2001 to 2005. She currently holds the following positions: Independent Director at Gilead Sciences, Inc. (since 2018), Member of The Royal Society of Chemistry (since 2014), Professor at California Institute of Technology (since 1989), Member of the National Academy of Sciences (since 2002), Member of the American Academy of Arts & Sciences (since 1991), Member of the National Academy of Medicine (United States) (since 2012), and Vice President & Member of the American Philosophical Society (since 2000). Her former positions include Director at The Dow Chemical Co. (1993-2017), Director at Dow Wolff Cellulosics GmbH & Co. KG, Director at DuPont de Nemours, Inc. (2018-2019), Independent Director at Dow, Inc. (1993-2021), Professor at The Trustees of Columbia University in The City of New York (1983-1989), and Assistant Professor at Hunter College (1980-1982). Dr. Barton's education includes a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Barnard College (conferred in 1974). |
| Sandra J. Horning |
Sandra J. Horning is the founder of EQRx International, Inc. (founded in 2020) and EQRx, Inc. (founded in 2019). She is currently an Independent Director at Gilead Sciences, Inc., Revolution Medicines, Inc., Olema Pharmaceuticals, Inc., Moderna, Inc., and Cellarity Inc. She is also a Professor at Stanford University School of Medicine. Previously, she held positions as a Director at Foundation Medicine, Inc. (2015-2018), Chief Medical Officer & EVP-Global Development at Genentech, Inc. (2014-2019), Chief Medical Officer at Roche Holdings, Inc. (2009-2019), President at American Society of Clinical Oncology, Inc. (2005-2006), and Chief Medical Officer & Head-Product Development at Roche, Inc. (2013-2019). Dr. Horning received her undergraduate and doctorate degrees from the University of Iowa. |
| Ted W. Love |
Ted W. Love is currently serving as the Chairman of the Biotechnology Innovation Organization. He is also an Independent Director at Gilead Sciences, Inc., Avillion LLP, Structure Therapeutics, Inc., Royalty Pharma Plc, and Life Science Cares Bay Area. In his former positions, Dr. Love served as the Chairman, President & Chief Executive Officer of Nuvelo, Inc. from 2001 to 2009. He was also the President, Chief Executive Officer & Director of Global Blood Therapeutics, Inc. from 2013 to 2022. Additionally, he served as an Independent Director at Bio-Rad Laboratories, Inc. from 2010 to 2013, Seagen Inc. from 2020 to 2023, Mast Therapeutics, Inc. from 2012 to 2013, Santarus, Inc. from 2005 to 2014, Amicus Therapeutics, Inc. from 2012 to 2020, Humanigen, Inc. from 2009 to 2015, Portola Pharmaceuticals LLC from 2019 to 2020, ARCA biopharma, Inc. from 2001 to 2009 and again from 2009 to 2011, Cascadian Therapeutics LLC from 2013 to 2018, Affymax, Inc. from 2006 to 2013, and as a Director at Predix Pharmaceuticals, Inc., Stanford Health Care, California Healthcare Institute, California Institute for Regenerative Medicine, and The Biotechnology Institute. Dr. Love received his undergraduate degree from Haverford College and his doctorate from Yale School of Medicine. |
| Harish M. Manwani |
Harish M. Manwani is currently the Chairman-Executive Board at Indian School of Business. He is also an Independent Director at Gilead Sciences, Inc., Whirlpool Corp., and a Director at The Nielsen Company (US) LLC, Tata Sons Pvt Ltd., Blackstone, Inc., EDBI Pte Ltd., and EDB Investments Pte Ltd. In his former positions, Mr. Manwani served as the President & Chief Executive Officer at Unilever HPC Co. from 2004 to 2005. He was the Non-Executive Chairman at Hindustan Unilever Ltd. from 2005 to 2018. He also held the position of Chairman at Alinamin Pharmaceutical Co., Ltd. Additionally, he served as an Independent Director at QUALCOMM, Inc. from 2014 to 2022, a Director at ING Groep NV in 2010, an Independent Non-Executive Director at Pearson Plc from 2013 to 2018, an Independent Non-Executive Director at Nielsen NV, an Independent Non-Executive Director at Nielsen Holdings Ltd. from 2015 to 2021, a Director at Singapore Economic Development Board from 2013 to 2019, a Director at Nielsen NV (Old), a Director at Human Capital Leadership Institute from 2012 to 2014, and the Chief Operating Officer at Unilever Plc from 2011 to 2014. He was also a Member of the Economic Development Board of Singapore from 2013 to 2019. Mr. Manwani completed his undergraduate and graduate degrees at the University of Mumbai. He also holds a graduate degree from Harvard Business School. |
| Kevin E. Lofton |
Kevin E. Lofton is currently the Lead Independent Director at Gilead Sciences, Inc. He is also a Director at Morehouse School of Medicine, Conifer Health Solutions LLC, and Medtronic Plc. Additionally, he serves as a Trustee at the Catholic Health Association of the USA. In his former roles, Mr. Lofton served as the Co-Chief Executive Officer & Trustee at Dignity Health. He was also the Chief Executive Officer & Trustee at CommonSpirit Health (Illinois) from 2019 to 2020. He held the position of Chief Executive Officer at UAB Health Systems and Howard University Hospital. He served as the Chief Executive Officer at UAB Hospital from 1993 to 1998. From 1998 to 2019, he was the Chief Executive Officer at Catholic Health Initiatives. Mr. Lofton also served as an Independent Director at Rite Aid Corp. from 2013 to 2022. He was a Trustee at the American Hospital Association, Inc. from 2007 to 2010. Additionally, he held the position of Chief Operating Officer & Executive Vice President at Shands Jacksonville Medical Center, Inc. and University Medical Center from 1986 to 1990. Mr. Lofton completed his undergraduate degree at Boston University and his graduate degree at Georgia State University. |
